本文選題：甲狀腺腫瘤　切入點(diǎn)：半乳糖凝集素　出處：《中國臨床醫(yī)學(xué)影像雜志》2017年01期

【摘要】：目的:探討超聲引導(dǎo)下穿刺細(xì)胞檢測Galectin-3和CK19在良、惡性甲狀腺濾泡性腫瘤的表達(dá)差異。方法 :選取甲狀腺濾泡狀癌(FTC)患者34例分為FTC組,甲狀腺濾泡性腺瘤(FA)40例分為FA組。檢測患者的超聲引導(dǎo)下細(xì)針穿刺細(xì)胞學(xué)檢查(FNAC)標(biāo)本和病理組織的Galectin-3、CK19表達(dá),分析兩組FNAC標(biāo)本的Galectin-3、CK19表達(dá)情況;以病理組織的Galectin-3和CK19表達(dá)情況為標(biāo)準(zhǔn),分析FNAC標(biāo)本表達(dá)Galectin-3和CK19的敏感性、特異性和準(zhǔn)確性。比較Galectin-3、CK19與FTC患者的臨床參數(shù)資料的關(guān)系。結(jié)果 :Galectin-3、CK19在FTC組和FA組的表達(dá)有顯著差異(Galectin-3:Z=-4.478,P=0.000;CK19:Z=-2.307,P=0.021);FNAC標(biāo)本檢測CK19、Galectin-3表達(dá)的敏感性、特異性、準(zhǔn)確性分別為85.7%、76.3%、81.3%,和84.7%、91.2%、87.5%。Galectin-3的表達(dá)在FTC患者的不同性別、年齡、腫瘤直徑之間無明顯差異(P0.05);而Galectin-3陽性率在有淋巴結(jié)轉(zhuǎn)移(93.3%)和TNMⅢ+Ⅳ分期(100%)的患者比無淋巴結(jié)轉(zhuǎn)移(63.2%)和TNMⅠ+Ⅱ分期(66.7%)患者的高,差異有統(tǒng)計學(xué)意義(分期:T=4.359,P=0.037;淋巴結(jié)轉(zhuǎn)移:T=4.242,P=0.039);CK19的表達(dá)在這些臨床參數(shù)之間均無明顯差異(P0.05)。結(jié)論:FTC患者的FNAC標(biāo)本檢測Galectin-3和CK19的表達(dá)明顯高于FA患者,可為臨床工作用鑒別診斷FTC和FA提供一定的協(xié)助作用。
[Abstract]:Objective: to investigate the expression of Galectin-3 and CK19 in benign and malignant thyroid follicular tumors.Methods: 34 cases of thyroid follicular carcinoma were divided into FTC group and 40 cases of thyroid follicular adenoma were divided into FA group.To detect the expression of Galectin-3C19 in the specimens of FNAC and pathological tissues under the guidance of ultrasound, and to analyze the expression of Galectin-3CK-19 in the two groups of FNAC, the expression of Galectin-3 and CK19 in the pathological tissues was taken as the standard.The sensitivity, specificity and accuracy of FNAC expression of Galectin-3 and CK19 were analyzed.To compare the relationship between Galectin-3 P CK19 and clinical data of FTC patients.The positive rate of Galectin-3 was higher in patients with lymph node metastasis (93. 3%) and TNM 鈪，

本文編號：1723175